Valuation: CASI Pharmaceuticals, Inc.

Market Cap	22.61L 20.07L 18.78L 17.03L 32.15L 22Cr 32.39L 2.26Cr 87.75L 11Cr 84.87L 83.05L 36Cr	P/E 2024	-1.11x	P/E 2025	-0.33x
Enterprise Value	2.41Cr 2.14Cr 2Cr 1.82Cr 3.43Cr 232.47Cr 3.45Cr 24Cr 9.36Cr 118.59Cr 9.05Cr 8.86Cr 381.24Cr	EV / Sales 2024	1.75x	EV / Sales 2025	1.9x
Free-Float	53.46%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Chart: CASI Pharmaceuticals, Inc.

Dynamic Chart

Latest news: CASI Pharmaceuticals, Inc.

14/08	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
14/08	Casi Pharmaceuticals, Inc. Announces Management Changes	CI
02/06	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
15/05	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
15/05	CASI Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
21/04	CASI Pharmaceuticals, Inc. announced that it has received $20 million in funding from ETP Global III Fund LP	CI
21/04	CASI Pharmaceuticals, Inc. Announces Termination of Dr. Alexander A. Zukiwski, MD as Global Chief Medical Officer, Effective April 20, 2026	CI
03/03	CASI Pharmaceuticals, Inc. Announces CEO Changes	CI
03/03	Casi Pharmaceuticals, Inc. Announces Resignation of Director David Cory, Effective March 31, 2026	CI

More news

Press Releases: CASI Pharmaceuticals, Inc.

14/08	CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results	AQ
01/07	CASI Pharmaceuticals : Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Active and Chronic Active Antibody-mediated Rejection	PU

More press releases

Managers and Directors: CASI Pharmaceuticals, Inc.

Manager	Title	Age	Since
David Cory CEO	Chief Executive Officer	62	21/07/2025
Kun Qian DFI	Director of Finance/CFO	44	16/05/2025
Chun Hua Wang COO	Chief Operating Officer	54	01/01/2017

Director	Title	Age	Since
Yue Wu BRD	Director/Board Member	62	01/04/2013
Zhen Bo Su BRD	Director/Board Member	50	21/03/2023
Thomas Folinsbee BRD	Director/Board Member	59	21/03/2023

More insiders

CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Companyâ€™s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Companyâ€™s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
06/26/06	$0.1100	+4.56%	821
05/26/05	$0.1052	-10.09%	201
02/26/02	$0.1170	0.00%	1,025
01/26/01	$0.1170	-	3,259
30/26/30	$0.000000	-100.00%	126

Delayed Quote Nasdaq

More quotes

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - CASI Pharmaceuticals, Inc.

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Nasdaq 11:39:08 06/10/2026 pm IST			5-day change	1st Jan Change
0.1100 ^USD	+4.56%		-31.25%	-87.06%

1 week	-4.10%
1 month	-28.10%
3 months	-44.98%
6 months	-21.85%
Current year	-87.06%

1 week	0.11	0.12
1 month	0.11	0.16
3 years	0.05	8.48
5 years	0.05	12.1
10 years	0.05	88.92

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CASI PHARMACEUTICALS, INC.	+4.56%	-31.25%	-93.99%	-95.94%	21.62L
ELI LILLY AND COMPANY	+1.26%	-2.29%	+36.97%	+104.79%	1,01900Cr
JOHNSON & JOHNSON	+0.73%	-4.78%	+35.41%	+61.62%	61TCr
ABBVIE INC.	+0.35%	+1.29%	+15.86%	+79.90%	47TCr
MERCK & CO., INC.	+1.72%	-4.92%	+59.84%	+36.64%	34TCr
ROCHE HOLDING AG	+0.26%	-1.58%	+21.97%	+41.79%	34TCr
NOVARTIS AG	+0.60%	-3.48%	+11.37%	+34.33%	27TCr
ASTRAZENECA PLC	+1.65%	-4.27%	-5.47%	+9.69%	24TCr
AMGEN INC.	-0.09%	-4.97%	+36.88%	+50.52%	22TCr
GILEAD SCIENCES, INC.	-0.28%	-4.66%	+26.99%	+92.98%	18TCr
Average	+0.38%	-3.71%	+14.58%	+41.63%	40.92TCr
Weighted average by Cap.	+0.05%	-3.43%	+29.67%	+67.25%

	2024	2025
Net sales	2.85Cr 2.53Cr 2.37Cr 2.15Cr 4.06Cr 275.09Cr 4.09Cr 28Cr 11Cr 140.34Cr 11Cr 10Cr 451.15Cr	2.07Cr 1.84Cr 1.72Cr 1.56Cr 2.95Cr 199.66Cr 2.97Cr 21Cr 8.04Cr 101.85Cr 7.77Cr 7.61Cr 327.44Cr
Net income	-3.93Cr -3.48Cr -3.26Cr -2.96Cr -5.58Cr -378.44Cr -5.62Cr -39Cr -15Cr -193.06Cr -15Cr -14Cr -620.64Cr	-4.81Cr -4.27Cr -3.99Cr -3.62Cr -6.83Cr -463.27Cr -6.88Cr -48Cr -19Cr -236.33Cr -18Cr -18Cr -759.76Cr
Net Debt	60.5L 53.71L 50.26L 45.55L 86.03L 58Cr 86.65L 6.04Cr 2.35Cr 30Cr 2.27Cr 2.22Cr 96Cr	2.19Cr 1.94Cr 1.82Cr 1.65Cr 3.11Cr 210.67Cr 3.13Cr 22Cr 8.48Cr 107.47Cr 8.2Cr 8.03Cr 345.49Cr

CASI Pharmaceuticals, Inc. Share Price Nasdaq

Stocks

CASI

KYG1933S1012

Pharmaceuticals

Valuation: CASI Pharmaceuticals, Inc.

Chart: CASI Pharmaceuticals, Inc.

Latest news: CASI Pharmaceuticals, Inc.

Press Releases: CASI Pharmaceuticals, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: CASI Pharmaceuticals, Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise